Toshiyuki Isoe

Hokkaido University Hospital — Japan

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index1.1kcitations47works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(13), Colorectal Cancer Treatments and Studies(10), Gastric Cancer Management and Outcomes(9), Microbial Natural Products and Biosynthesis(5), PI3K/AKT/mTOR signaling in cancer(5)

Publications47 total

Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer
Japanese Journal of Clinical Oncology·2025· 3 citedOpen Access
Acellular, bioresorbable, ultra-purified alginate gel implantation for intervertebral disc herniation: Phase 1/2, open-label, non-randomized clinical trials
Nature Communications·2025· 4 citedOpen Access
Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single‐arm phase <scp>II</scp> trial
Experimental Dermatology·2023· 1 citedOpen Access
Supplementary Figure 1A from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1C from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1C from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Data from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1A from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Data from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1B from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1B from Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
2023Open Access
Protocol for treating lumbar spinal canal stenosis with a combination of ultrapurified, allogenic bone marrow-derived mesenchymal stem cells and in situ-forming gel: a multicentre, prospective, double-blind randomised controlled trial
BMJ Open·2023· 2 citedOpen Access
Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
Cancers·2022· 25 citedOpen Access
Exploratory clinical trial on the safety and capability of dMD-001 in lumbar disc herniation: Study protocol for a first-in-human pilot study
Contemporary Clinical Trials Communications·2021· 14 citedOpen Access
Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency
Brain and Development·2020· 8 cited
Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey
Molecular Genetics and Metabolism Reports·2019· 14 citedOpen Access
Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial
BMJ Open·2019· 11 citedOpen Access
Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma
Clinical Trials·2019· 1 cited
page 1 of 3Next →

Frequent Co-authors

Kunihiko Hayashi(14), Leni van Doorn(14), Maja J.A. de Jonge(13), Jaap Verweij(13), Ferry A.L.M. Eskens(12), Pankaj Bhargava(12), Monette Cotreau(12), Brooke Esteves(12), Herman Burger(12), Maarten Thomeer(11), Yoichi M. Ito(10), Norihiro Sato(9), Kazuhide Nakamura(8), Kazuo Kubo(7), Yoshiko Kobayashi(7), Hideko Murooka(6), Tsuyoshi Nishitoba(5), Takashi Miyakoshi(5), Hiroshi Hayashi(5), T Tsuruo(4)